Riskpilot← Back to searchSign inGet full accessAscelia Incentive AB
ABActiveOrg 5591294615Economic activity was not specified by tax authority · NACE 0000Est. 20170 employees
Revenue 2025
SEK 0
EBITDA margin
—
-21% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK -5K
-22% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -5K | -21% |
| Net profit | SEK -5K | -22% |
| Total assets | SEK 45K | -11% |
| Equity | SEK 45K | -10% |
| Employees | 0 | — |
Legal name
Ascelia Incentive AB
Org number
5591294615
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
17 oktober 2017
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska teckna, förvärva och överlåta optioner och andra värdepapper utställda av bolag inom den koncern som bolaget från tid till annan tillhör samt bedriva annan därmed förenlig verksamhet.
Address
Email
moc@ascelia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | −0 |
| EBITDA | −8 | −41 | −3 | −3 | −2 | −5 | −7 | −4 | −5 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — |
| EBIT | −8 | −41 | −3 | −3 | −2 | −5 | −7 | −4 | −5 |
| Net financials | — | — | — | — | — | — | — | — | −0 |
| Profit before tax | −8 | 9 | −3 | −3 | −2 | −5 | 18 | −4 | −5 |
| Tax | −0 | −1 | −0 | −0 | −0 | −0 | −1 | −0 | — |
| Net profit | −8 | 8 | −3 | −3 | −2 | −5 | 17 | −4 | −5 |
| Item | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 49 | 95 | 74 | 49 | 47 | 45 | 56 | 51 | 45 |
| Equity | 43 | 51 | 47 | 45 | 43 | 37 | 54 | 50 | 45 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Short-term debt | 7 | 45 | 26 | 4 | 5 | 8 | 1 | 1 | 0 |
| Total debt | 7 | 45 | 26 | 4 | 5 | 8 | 1 | 1 | — |
EBITDA margin
-483500.0%
This company
15.8%
Market median
-3060227% vs market
20182025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182025
Return on equity
-10.8%
This company
18.4%
Market median
-159% vs market
20182025
Net profit margin
-486200.0%
This company
8.1%
Market median
-6002569% vs market
20182025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-07-01 – 2019-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-10-01 – 2018-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CJ Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2026 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ascelia Pharma AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ascelia Pharma AB
Ascelia Incentive AB Board members of Ascelia Incentive AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Johan Fredrik Fogelberg | Chief Auditor | 0 companies |
| Magnus Olafsson Corfitzen | Board of Directors | 0 companies |
| Despina Georgiadou Hedin | Deputy Board Member | 0 companies |
| Julie Nana Waras Brogren | Deputy Board Member | 0 companies |
| Peter James Arthur Benson | Chairman | 0 companies |
| Anton Simon Joakim Hansson | Deputy Board Member | 0 companies |